UnknownPhase 2NCT02610556

Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-sen University
Principal Investigator
Fang-Yun Xie, M.D.
Sun Yat-sen University Cancer Center,Guangzhou, Guangdong, China
Intervention
Cisplatin 2(drug)
Enrollment
130 enrolled
Eligibility
18-65 years · All sexes
Timeline
20162022

Study locations (1)

Collaborators

Affiliated Cancer Hospital & Institute of Guangzhou Medical University · The First Affiliated Hospital of Guangzhou Medical University · The First Affiliated Hospital of Guangdong Pharmaceutical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02610556 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma

← Back to all trials